- Deep - Drug-releasing electrode with enhanced properties.
This project is about the development of an implantable electrode with quantitative drug eluting capacity. Polypyrrole coating of platinum nanostructures forms the basis of this innovative technology. Two lines of application are foreseen. One is to exploit the release of an anti-inflammatory drug in order to limit the tissue reaction around implanted nerves, thus aiming at improving the electrode performances. The second pertains to local treatments requiring precise drug delivery in time and location.
- Walbiostent - Study of interaction between stent, arterial wall and blood related to atherosclerosis disease.
This project will target 2 main aspects, on the one hand the metal effect on thrombogenecity,
which leads to hyperplasia and restenosis; on the other hand the effect of the multilayer stent on the shear stress flow which prevents hyperplasia. Several studies show that the thrombogenicity of the metal could be prevented by covering it with a non-thrombogenic biocompatibility nanofilm.
The outcome of this project will have major impacts. Clinically: the device has a non-thrombogenic metal surface, which ensures long-term patency. Cardiatis’ development: the company intends to become a leader in the treatment of cerebral and peripheral aneurysm by stenting. To our knowledge, Cardiatis is the only company developing such a device for the treatment of cerebral aneurysm (saccular and bifurcated) without coil and a non-covered stent allowing to heal all other peripheral aneurysms. Image and partenership: Cardiatis aims at becoming a leader in the stent business and demonstrating that it is capable of bringing together different teams achieving fruitful collaboration.
- JOIN T-AIC - Development of new therapeutic approaches for the treatment of inflammatory mono-arthritis combining “novel” anti-TNF-α and viscoelastic scaffold.
Mono-arthritis is generally treated by intra-articular injections of corticosteroids or of hyaluronic acid. However, due to their limited efficacy, or due to their toxicity, injectable corticosteroids are only administered a few times, which leads, in absence of alternative, to premature surgical intervention. Recent developments in molecular biology have allowed discovering novel mechanisms of action for known therapeutic compounds. Novel anti-inflammatory properties have recently been identified in a known, unrelated therapeutic class whom a few molecules are commercialized and off patent (AIC): these properties are an inhibition of TNF-α and IL-1β secretion, pro-inflammatory agents, and an increase in TGF-α secretion, a pro-regenerative factor. The interest of this project definitely lies in the opportunity of a significantly shortened development track and therefore of an early commercialization. The first generation JOIN T-AIC candidate is based on commercialized and off-patent compounds, for which the needs for pre-clinical and clinical studies will be significantly reduced.
- StarfloPlus - Glaucoma Management Implant System.
Research of a next generation Glaucoma Management Implant System that incorporates the latest advances in biomaterials, MEMS sensor, and electronics technologies. The goal of the implant system is to provide a novel combination of therapeutic and diagnostic benefits for Glaucoma patients and caregivers, while significantly reducing the cost of vision care for global healthcare systems and societies.